<?xml version="1.0" encoding="UTF-8"?>
<p id="p0215">The antiviral activity (EC
 <sub>50</sub>) of favipiravir against influenza and Ebola viruses is different from the range of 0.014–0.55 μg/mL in medium without adenosine and guanosine and 10 μg/mL, respectively (
 <xref rid="bb0170" ref-type="bibr">Furuta et al., 2002</xref>; 
 <xref rid="bb0430" ref-type="bibr">Oestereich et al., 2014</xref>). Addition of 10 x EC
 <sub>50</sub> (63.7 μM) of adenine, guanine, adenosine, guanosine, and inosine in the assay medium abolishes the anti-influenza virus activity of favipiravir (
 <xref rid="bb0175" ref-type="bibr">Furuta et al., 2005</xref>). The intracellular concentration of ATP is 1–9 mM in various tissues (
 <xref rid="bb0050" ref-type="bibr">Beis &amp; Newsholme, 1975</xref>), suggesting favipiravir may need a higher concentration in vivo. Pharmacokinetic values of favipiravir for the maximum drug concentration (
 <italic>C</italic>max), the area under the curve (
 <italic>AUC</italic>), the maximum drug concentration time (
 <italic>T</italic>max), and the half-life period (
 <italic>t</italic>1/2) are 65 μg/mL, 450–550 μg·hr/mL, 1 h, and 4.8–5.6 h, respectively (Avigan Tablets 200 mg package insert).
</p>
